
Corvus Pharmaceuticals rose 14.1% from $8.91 to $10.17, ahead of the S&P 500's +10.0%. Its worst day was May 14 (−13.8%), and its low came Jan 13 at $6.50.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Corvus Pharmaceuticals closed at its lowest level of the year, 27.0% below where the year started.
−3.7% · S&P 500 −0.2%
Corvus Pharmaceuticals closed at its highest level of the year, 186.4% above where the year started.
Story events cover the past 12 months · Times ET
+15.2% · S&P 500 +0.5%
EPS of $-0.15 missed the $-0.14 estimate on $0.00 revenue (est. $620,000.00).
−4.3% · S&P 500 −0.6%
EPS of $-0.15 beat the $-0.15 estimate on $0.00 revenue (est. $620,000.00).
+6.6% · S&P 500 +0.8%
EPS of $-0.19 missed the $-0.17 estimate on $0.00 revenue.
+0.4% · S&P 500 +0.6%
EPS of $-0.22 missed the $-0.21 estimate on $0.00 revenue.
+8.3% · S&P 500 +0.3%
Where it ended: a close of $10.17 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.23).
Nothing in the past 12 months.
All CRVS dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CRVS and SPY from Benzinga historical bars. Not investment advice.